BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38315612)

  • 41. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
    Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
    Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes.
    Pourhassan H; DeFor T; Trottier B; Dolan M; Brunstein C; Bejanyan N; Ustun C; Warlick ED
    Bone Marrow Transplant; 2017 Apr; 52(4):532-538. PubMed ID: 27941767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Art of Transplantation: Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation.
    Ragon BK
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):e71-e72. PubMed ID: 30562588
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Vydra J; Válková V; Čemusová B; Kolář M; Nováková L; Soukup P; Šálek C; Vraná M; Pytlík R; Lesný P; Vítek A; Cetkovský P; Marková M
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):365-371. PubMed ID: 30905537
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
    Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review.
    Parmar S; de Lima M; Deeg HJ; Champlin R
    Semin Oncol; 2011 Oct; 38(5):693-704. PubMed ID: 21943676
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single-center retrospective study.
    Huang J; Huang F; Fan Z; Xu N; Xuan L; Liu H; Shi P; Jiang L; Zhang Y; Sun J; Liu Q
    Cancer Med; 2020 Sep; 9(17):6244-6255. PubMed ID: 32686915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What the internist should know about stem cell transplant in the elderly patient.
    Medinger M; Passweg J
    Eur J Intern Med; 2018 Dec; 58():43-47. PubMed ID: 29960832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single-unit unrelated cord blood transplantation versus HLA-matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry-based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy.
    Konuma T; Itonaga H; Shimomura Y; Fujioka M; Aoki K; Uchida N; Onizuka M; Jinguji A; Tanaka M; Ueda Y; Katayama Y; Sawa M; Tanaka H; Nakamae H; Kawakita T; Maruyama Y; Takahashi S; Ishimaru F; Kanda J; Ichinohe T; Atsuta Y
    Hematol Oncol; 2024 Jan; 42(1):e3217. PubMed ID: 37592904
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
    Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes.
    Getta BM; Kishtagari A; Hilden P; Tallman MS; Maloy M; Gonzales P; Castro-Malaspina H; Perales MA; Giralt S; Tamari R; Klimek V
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1078-1086. PubMed ID: 28336325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transplant strategies for patients with myelodysplastic syndromes.
    Deeg HJ
    Curr Opin Hematol; 2006 Mar; 13(2):61-6. PubMed ID: 16456370
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
    Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
    Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
    Locke F; Agarwal R; Kunnavakkam R; van Besien K; Larson RA; Odenike O; Godley LA; Liu H; Le Beau MM; Gurbuxani S; Thirman MJ; Sipkins D; White C; Artz A; Stock W
    Bone Marrow Transplant; 2013 Nov; 48(11):1437-43. PubMed ID: 23771005
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.
    Jentzsch M; Döhring C; Linke R; Hille A; Grimm J; Pönisch W; Vucinic V; Franke GN; Behre G; Niederwieser D; Schwind S
    Am J Hematol; 2019 Dec; 94(12):1344-1352. PubMed ID: 31495933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
    Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
    J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes.
    Platzbecker U
    Semin Hematol; 2012 Oct; 49(4):342-9. PubMed ID: 23079064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
    Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.